Full-Time

Process Development & Manufacturing Specialist 1

Maravai LifeSciences

Maravai LifeSciences

51-200 employees

Offers oligonucleotide synthesis and immunohistochemistry

No salary listed

Jupiter, FL, USA

In Person

On-site position based in Jupiter, Florida.

Bachelor's, Associate's

Category
Biology & Biotech (1)

Get referred to Maravai LifeSciences

See people who can refer or advise you

Requirements
  • High school diploma with 2+ years of relevant industry experience, or Associate’s/Bachelor’s degree in Biochemistry, Biology, or related scientific discipline preferred.
  • Hands-on experience or exposure to enzyme production/manufacturing processes such as fermentation, filtration, chromatography, or enzymatic reactions preferred.
  • Basic understanding of GMP, ISO, or regulated manufacturing environments and documentation practices (GDP).
  • Ability to follow SOPs and execute protocols with attention to detail and data accuracy.
  • Strong organizational and problem-solving skills with the ability to manage multiple tasks in a dynamic environment.
  • Effective communication and teamwork skills; proficiency with Microsoft Office and familiarity with ERP or document control systems is a plus.
Responsibilities
  • Execute enzyme production and manufacturing processes, including fermentation, enzymatic reactions, filtration, and chromatography, following established protocols.
  • Prepare materials, equipment, and production areas to support manufacturing activities and ensure readiness for scheduled operations.
  • Accurately document production and experimental activities in batch records, logs, and reports in accordance with Good Documentation Practices (GDP).
  • Operate and maintain laboratory and manufacturing equipment, performing basic troubleshooting and routine maintenance.
  • Support process characterization and development activities under supervision to improve product quality and consistency.
  • Collaborate with Manufacturing, Quality, and Supply Chain teams to support production schedules and material flow.
  • Maintain compliance with cGMP (as applicable), ISO standards, and safety requirements.
  • Perform other duties as assigned to support production and process development objectives.

Maravai LifeSciences provides tools and services for life sciences research and bioproduction, including supplying oligonucleotides for PCR, next-generation sequencing (NGS), and gene editing, as well as immunohistochemistry for cancer research, serving academic institutions, biotechnology firms, and pharmaceutical companies. Oligonucleotide synthesis creates short DNA or RNA strands used in PCR, sequencing, and genome editing workflows; immunohistochemistry uses labeled antibodies to detect proteins in tissue samples. It differentiates itself by combining investment and operational support to incubate and scale life science companies while offering essential research tools. Its goal is to catalyze the development of life science companies to advance human health by providing capital, expertise, and essential research tools.

Company Size

51-200

Company Stage

IPO

Headquarters

San Diego, California

Founded

2014

Get referred to Maravai LifeSciences

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q1 2026 revenue rose 40.5% to $65.8 million, and guidance increased.
  • Q2 2026 revenue reached $51.4 million, while adjusted EBITDA rose to $8.7 million.
  • Refinancing extended debt maturity to 2032, giving Maravai flexibility for 2026 investments.

What critics are saying

  • Maravai’s February 2025 revenue-restatement scandal exposed internal-control failures and goodwill issues.
  • The August 2025 restructuring cut 25% of staff, risking execution gaps through Q3 2026.
  • COVID CleanCap demand remains volatile; a sustained drop destroys TriLink’s growth engine.

What makes Maravai LifeSciences unique

  • TriLink’s July 20, 2026 CleanCap patents secure dominant mRNA capping IP globally.
  • Cygnus’s mock viral particle technology shields bioprocess testing from direct reagent commoditization.
  • Officinae Bio’s February 24, 2025 acquisition adds AI-enabled mRNA design to TriLink.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Company Equity

Fertility Treatment Support

Family Planning Benefits

401(k) Retirement Plan

Paid Vacation

Growth & Insights and Company News

Headcount

6 month growth

-2%

1 year growth

-2%

2 year growth

-2%
Business Wire
Jun 23rd, 2026
Maravai LifeSciences Announces Refinancing of Credit Agreement, Extending Maturity to 2032

Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today anno...

Maravai LifeSciences Holdings, Inc.
Jun 9th, 2026
Maravai LifeSciences Announces Pricing of Secondary Offering of Class A Common Stock by Selling Stockholders

SAN DIEGO, Calif., Sept. 10, 2021 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of…...

Maravai LifeSciences Holdings, Inc.
Jun 9th, 2026
424B4

The selling stockholders named in this prospectus are offering 20,000,000 shares of our Class A common stock. We are not selling any shares under this prospectus and we will not receive any proceeds from the sale of shares by the selling stockholders.

MarketScreener
Jun 3rd, 2026
Maravai LifeSciences cuts debt to $150M and extends maturity to 2032

Maravai LifeSciences has refinanced its credit agreement, securing a $150 million term loan facility and a $30 million revolving credit facility. The life science reagents provider used the new term loan borrowings and approximately $98.5 million in cash to prepay its existing credit agreement due in October 2027. The transaction reduces Maravai's long-term debt from $242.9 million to $150 million and extends the maturity date to June 2032. Chief Financial Officer Raj Asarpota said the refinancing strengthens the company's financial foundation whilst preserving capital access for strategic priorities and growth initiatives. Maravai provides critical products for drug therapy development, diagnostics and vaccine research, serving major biopharmaceutical, vaccine and cell and gene therapy companies globally.

Associated Press
May 7th, 2026
Maravai LifeSciences raises 2026 guidance after Q1 revenue jumps 40.5% to $65.8M

Maravai LifeSciences, a global provider of life science reagents and services, reported first quarter 2026 revenue of $65.8 million, up 40.5% year-over-year, driven by strong demand in its TriLink business. The company posted a net loss of $6.4 million but achieved adjusted EBITDA of $20.3 million and returned to positive free cash flow, generating $4.2 million. TriLink revenue grew 65% to $47.5 million, including $14.3 million from COVID vaccine programme orders. Excluding COVID-related sales, TriLink base revenue increased 15% year-over-year. Cygnus revenue rose 1.4% to $18.4 million. Following the strong performance, Maravai raised its full-year 2026 guidance, now expecting revenue of $205 million to $215 million and adjusted EBITDA of $30 million to $32 million.